drugset / Trial / NCT06928142
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
Phase 2
Active not recruiting
83 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
Timeline
- Start
- 2025-04-23
- Primary completion
- 2027-03-13
- Completion
- 2027-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sibeprenlimab | Monoclonal antibody | 400 mg | Subcutaneous |